Sherpa Healthcare Partners

Active

Website LinkedIn

Updated: Apr 1, 2026 ·

Financial History

Total Raised

N/A

Valuation

N/A

Investments Made

Date	Company	Round	Lead Investor(s)	Co-Investor(s)
Feb 25, 2026	Avisi Technologies	$10.7M Series A	Justin Fukuyama	Accanto Partners, Gemseki, Golden Seeds, Good Growth Capital, Life Sciences Greenhouse of Central Pennsylvania, OneOneFive, Quaker Capital Investments, SBI US Gateway Fund, Darren Cai
Jan 7, 2026	Spiro Medical	$67.0M Series A	Andera Partners, Omega Funds, Xiangyu Ouyang	—
May 7, 2025	PAQ Therapeutics	$39.0M Series B	Yuexing Su, Olga Danilchanka	Johnson & Johnson Innovation, Lilly Asia Ventures
Jan 25, 2024	ZWI Therapeutics, Inc.	$10.0M Series A	—	Co-win Ventures
Sep 8, 2023	GRIT Biotechnology	$60.0M Series B	CICC Capital	Decheng Capital, HeFangTian Venture Partnership, Liando Investment, Matrix Partners China, Yuanhe Capital
Sep 4, 2022	Neukio Biotherapeutics	$50.0M Series A	—	IDG Capital, Lilly Asia Ventures, Surplus Capital
Mar 3, 2022	Leadsynbio	$63.3M Series C	Sherpa Healthcare Partners	Asia Green Fund
Feb 10, 2022	Hong Kong Asia Heart Centre	$400.0M Series D	Country Garden Venture Capital, Jiaqi Zheng	General Atlantic, Hudson Bay Capital, ICBC International, Legend Capital, Taikang
Nov 30, 2021	Fuse Biotherapeutics	$9.5M Seed	—	GC&H Investments, Ivy Venture Group, Darren Cai, Sirona Capital
Nov 18, 2021	BAKX Therapeutics	$25.0M Series A	Yibing Shan	Philippe Lopes-Fernandes
Sep 1, 2021	Alamar Biosciences	$80.0M Series B	Sherpa Healthcare Partners	Forbion, Illumina Ventures, Qiming Venture Partners, Morningside Ventures, Samsara BioCapital
Jul 16, 2021	PAQ Therapeutics	$30.0M Series A	Cheng Xing	Huagai Capital, Matrix Partners China, MRL Ventures Fund, MSA Capital, Nest.Bio Ventures
Jul 1, 2021	Bota Biosciences	$100.0M Series B	Sequoia Capital	AIX Ventures, Amadeus Capital Partners, Atomico, Dell Technologies Capital, Hitachi Ventures, Meituan, Sequoia Capital China, Greg Brockman, Paul Holland, Shane Neman, 5Y Capital, Matrix Partners China, Source Code Capital
May 10, 2021	Alebund Pharmaceuticals	$60.0M Series B	Quan Capital	3E Bioventures Capital, Lilly Asia Ventures, Med-Fine Capital
May 1, 2021	Appia Bio	$52.0M Series A	Francisco Gimenez	8VC, NanoDimension, Freeflow Ventures, Two Sigma Ventures
Apr 21, 2021	EdiGene	$61.5M Series B	Andy Lin	3H Health Investment, Hongshan Capital Group (Sequoia Capital China), Huagai Capital, IDG Capital, Kunlun Capital, Lilly Asia Ventures
Mar 1, 2021	EpimAb Biotherapeutics	$120.0M Series C	Tony Rong, Sungwon Song	CVentures, Adrian Cheng, Cormorant Asset Management, Decheng Capital, Hidragon Capital, Hony Capital, Octagon Capital, SDIC Fund, ShangBay Capital, Yanchuang Capital
Jan 1, 2021	Visen Pharmaceuticals	$150.0M Series B	Hongshan Capital Group (Sequoia Capital China)	Qiming Venture Partners, Vivo Capital, Michael Wolff Jensen, CDG Capital, Cormorant Asset Management, HBM Healthcare Investments, Logos Capital, OrbiMed, Pivotal bioVenture Partners China, Sofinnova Ventures
Sep 23, 2020	Heyuan Biotechnology	$44.2M Series C	Loyal Valley Capital	GP Capital, Morningside
Jun 5, 2019	EpimAb Biotherapeutics	$74.0M Series B	Dongfang Li, Cheng Xing	SCVC
Jan 30, 2019	Yosemite Clinic	$14.9M Series B	Xiangyu Ouyang	—